Groenland, Stefanie L. http://orcid.org/0000-0001-9918-2374
Janssen, J. M.
Nijenhuis, C. M.
de Vries, N.
Rosing, H.
Wilgenhof, S.
van Thienen, J. V.
Haanen, J. B. A. G.
Blank, C. U.
Beijnen, J. H.
Huitema, A. D. R.
Steeghs, N.
Article History
Received: 28 December 2022
Accepted: 25 February 2023
First Online: 22 March 2023
Declarations
:
: No author has received support for the work in this manuscript. JBAGH served as a consultant advisor for Achilles Therapeutics, AIMM, Amgen, BioNTech, BMS, Bayer, Celsius Therapeutics, Gadeta, GSK, Ipsen, Immunocore, MSD, Merck Serono, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures and Vaximm, and received research funding from BMS, BioNTech, Novartis and MSD. CUB served as a consultant advisor for BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures, received research funding from BMS, Novartis and Nanostring, reports stock ownership of Uniti Cars and is cofounder of Immagene B.V. JHB is a part-time employee, shareholder and patent holder of Modra Pharmaceuticals (a spin-out company developing oral taxane formulations, not related to this work). NS served as a consultant advisor for AIMM Therapeutics, Boehringer Ingelheim, Ellipses Pharma, and received research funding for the institute from AB Science, Abbvie, Actuate Therapeutics, Amgen, Array, AstraZeneca/MedImmune, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, CellCentric, Cytovation, Deciphera, Genentech/Roche, GlaxoSmithKline, Incyte, Lilly, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Taiho, Takeda (outside the submitted work). All remaining authors have declared no conflict of interest.